Gingival Recession, Plastic SurgeryNCT07083050
Non-Inferiority of Fibroguide Collagen Membrane Compared to Autologous Connective Tissue Graft for Coverage of Multiple Adjacent Recession. Multicenter Trial.
A study testing Volume stable collagen matrix and Autologous Connective Tissue Graft from the Hard Palate in people with Gingival Recession, Plastic Surgery, run by Maurizio Tonetti at 2 sites in 2 countries.
Trial summary
This study deals with coverage of multiple denuded roots. The current standard treatment requires surgical correction and uses soft tissue taken from the roof of the mouth to enhance results. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Gingival Recession, Plastic Surgery
- What is being tested?
- Volume stable collagen matrix and Autologous Connective Tissue Graft from the Hard Palate
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 160 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 12 Jul 2015to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female, 18 to 70 years of age, with a minimum of two adjacent teeth with gingival recession (at least one with a depth ≥ 3 mm - RT1 or RT2 with 2 mm or less of interdental periodontal attachment loss) in anterior and premolar teeth in the maxilla and requiring surgical intervention, without medical contraindications to elective surgery. In case of recessions on five or more adjacent teeth, the teeth at the external sides will not be included in the study.
- At least 2 mm marginal keratinized tissue width and irrespective of soft tissue thickness prior therapy. The study should involve treatment naïve patients in terms of root coverage procedures. Prior therapy should include treatment of gingival inflammation, if present, instructions in non-traumatic oral hygiene, and reconstruction of the cemento-enamel junction with adhesive dental materials in case of cervical abrasion or erosion involving this structure
- Evidence of subject ability to achieve good oral hygiene and control gingivitis in the whole of the dentition (FMPS<25% and FMBS<25%)
- Ability to understand study procedures and to comply with them for the entire length of the study. Ability and willingness to give written informed consent.
Who cannot join
- Presence of untreated periodontitis
- Persistence of uncorrected gingival trauma from tooth brushing
- Interdental attachment loss greater than 2 mm or furcation involvement in the experimental teeth
- Presence of less than 2 mm of keratinized tissue width
- Presence of severe tooth malposition, rotation or clinically significant super-eruption
- Self reported current smoking exceeding 10 cigarettes/day or pipe or cigar smoking
Show all 17Show fewer
- Rheumatoid arthritis or known sensitization to collagen based medical products.
- Presence of medical contraindications to elective surgery
- Participation in another interventional clinical trial
- Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Inability or unwillingness of individual to give written informed consent.
- Uncontrolled diabetes mellitus
- Allergy to collagen
- Pregnancy or lactation or sexually active female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control (e.g., oral or parenteral contraceptives, diaphragm plus spermicide, condoms).
- Radiotherapy
- immunosuppressive therapy
- chronic steroid therapy (inhaler or systemic).
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
Italy1 site, 1 recruiting
- Recruiting
Ospedale Careggi
Florence
Luigi Barbato, DMD PhD, 39-3299457556, luigi.barbato@unifi.it
Francesco Cairo, DMD, 39-3392961343, Francesco.cairo@unifi.it
Spain1 site, 1 recruiting
- Recruiting
International University of Catalunya
Barcelona
Jose Nart, DMD PhD, 34-626331060, jose@nartperiodoncia.com
Gonzalo Blasi, DMD, 34-626331060, gonzaloblasi@uic.es
About this study
Official title: Connective Tissue Graft vs Volume Stable Collagen Matrix (Geistlich Fibro-Gide®) for Coverage of Multiple Gingival Recession Defects in Combination With Coronally Advanced Flap (CAF) Randomized Multicenter Controlled Clinical Trial Assessing Non-Inferiority in Root Coverage
This study deals with coverage of multiple denuded roots. The current standard treatment requires surgical correction and uses soft tissue taken from the roof of the mouth to enhance results. The hypothesis of this trial is that a synthetic collagen matrix (called Fibrogide) can be used to replace soft tissue taken from the subject. If the collagen matrix will prove to be equally as effective as the patient own tissue, it will be possible to avoid a more extensive surgery and decrease pain and discomfort.
Read the detailed description
Objectives Primary objective: to assess non-inferiority of differences in root coverage of recession defects comparing the use of Volume Stable Collagen Matrix (VCMX, Geistlich Fibro-Gide®) ed to the use of CTG at 12 months Secondary objectives: to assess if VCMX is non-inferior in terms of complete root coverage, percentage of root coverage and professional evaluation of aesthetics. Moreover, the study is also designed to test if VCMX Geistlich Fibro-Gide® reduces morbidity, shortens time to recovery and improves patient based related outcomes with respect to the use of autologous connective tissue graft harvested from the patient own palate when used to obtain root coverage of multiple adjacent gingival recessions. Moreover, as adverse events, complete root coverage, and professional evaluation of aesthetics will be assessed
Design and Outcomes This will be a parallel group, controlled, assessor-blind, randomized, multicenter, multinational, clinical trial.
The statistical design will be a non-inferiority trial in terms of the professional outcomes measuring root coverage and aesthetics and a superiority trial in terms of patients related outcomes.
Based on a recently completed and published RCT with similar design (Geistlich Mucograft® study), the sample size has been estimated in 80 subjects per treatment arm (about 200 recessions/arm) to be analyzed with a multilevel statistical approach and a non-inferiority margin of 0.25 mm in recession coverage. The non-inferiority margin has been set as 50% of the clinically relevant difference estimated at 0.5 mm.
Randomization will be performed by computer generated random codes, using random permuted blocks with a block size of 4 to avoid uneven splits and minimization for the key prognostic factor cigarette smoking. Allocation will be concealed to the surgeons until completion of preparation of the recipient bed by opaque envelopes. A central study registrar will perform patient registration.
Study locations will include academic centers and a practice-based research network in Italy, Germany, and Spain.
A single examiner, blind with respect to the treatment assignment, will perform all primary outcome measurements at each center. Trained personnel not involved with the surgical intervention will: i) administer patient questionnaires, ii) provide instructions and collect patient diaries. A single calibrated investigator with specific experience in using the specific score will centrally perform assessment of esthetic scores on standardized digital images.
A biostatistician blind with respect to treatment assignment will perform the analysis.
Interventions and Duration The two intervention groups will consist of surgery with connective tissue graft from the palate (standard of care control) and surgery with the application of Geistlich Fibro-Gide®. Experienced clinicians will deliver treatment consisting of root coverage surgery using coronally advanced flaps, the most utilized procedure for coverage of multiple recessions. Surgery will be standardized and the same procedures/materials will be employed to ensure consistency essentially as performed in the completed Mucograft study.
The total duration of the Followfollow-up of individual patients will be up to 1 year and extended to 3 years for the collection of long-term follow-up data.
Sample Size and Study Population Study population will consist of 160 subjects with a minimum of two adjacent RT1 and RT2 (with periodontal attachment <2 mm) recessions of the gingival margin (average 2.5 recessions per subject, of which one should be 3 mm or deeper) requiring surgical intervention for root coverage. Heavy smokers (>10 cigarette/day) will be excluded.
- Conditions
- Gingival Recession, Plastic Surgery
- Being tested
- Volume stable collagen matrix, Autologous Connective Tissue Graft from the Hard Palate
- Keywords
- Gingival recession, Root coverage, Collagen Construct, Connective tissue graft, Morbidity
- Medical subject headings
- Gingival Recession
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Volume stable collagen matrixDevice
Also called Fibrogide
Volume stable collagen matrix obtained from porcine collagen after proprietary cross-linking by device manufacturer
Autologous Connective Tissue Graft from the Hard PalateProcedure or surgery
Also called CTG
Autologous connective tissue surgically harvested from the hard palate and transplanted in the area of gingival recession
| Study group | Role | What they receive |
|---|---|---|
| Coronally Advanced Flap plus Collagen Matrix | Experimental | Coronally Advanced Flap plus Collagen Matrix Tissue Substitute Receives: Device: Volume stable collagen matrix |
| Coronally Advanced Flap plus Autologous Connective Tissue Graft | Active comparator | Current standard of care Receives: Procedure: Autologous Connective Tissue Graft from the Hard Palate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Root coverage
Difference in reduction in gingival recession (root coverage) between baseline and 12 months
Measured: 12 months
Secondary outcomes (3)
Complete root coverage
Frequency of teeth and subjects with complete coverage of exposed root surface
Measured: 12 months
Time to recovery
Time necessary for remission of post-surgical pain and discomfort
Measured: The first two post-operative weeks
Oral Health Related Quality of Life
Oral Health Impact Profile (OHIP-14) instrument - Scale 0-10 with higher scores indicating a better outcome
Measured: 3, 6, 12, 24, and 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2025
- Study start12 Jul 2015
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gingival Recession, Plastic SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Maurizio Tonetti
- Sponsor type
- Research network
- Collaborators
- University of Florence, Universitat Internacional de Catalunya
- Responsible party
- Sponsor-investigator, Maurizio Tonetti, The European Research Group on Periodontology (ERGOPerio)
- Investigators
- Maurizio Tonetti, DMD PhD, Principal investigator, The European Research Group on Periodontology (ERGOPerio)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07083050
- Sponsor's protocol ID
- Fibroguide
- Status last verified
- Aug 2025
- First submitted
- 16 Jul 2025
- Last updated
- 7 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Connective Tissue Graft vs Volume Stable Collagen Matrix (Geistlich Fibro-Gide®) for Coverage of Multiple Gingival Recession Defects in Combination With Coronally Advanced Flap (CAF) Randomized Multicenter Controlled Clinical Trial Assessing Non-Inferiority in Root Coverage
- ClinicalTrials.gov ID
- NCT07083050
- Acronym / sponsor ID
- Fibroguide
- Conditions
- Gingival Recession, Plastic Surgery
- Keywords
- Gingival recession, Root coverage, Collagen Construct, Connective tissue graft, Morbidity
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 160 participants (estimated)
- Lead sponsor
- Maurizio TonettiResearch network
- Collaborators
- University of Florence, Universitat Internacional de Catalunya
- Study start
- 12 Jul 2015 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 24 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study deals with coverage of multiple denuded roots. The current standard treatment requires surgical correction and uses soft tissue taken from the roof of the mouth to enhance results. The hypothesis of this trial is that a synthetic collagen matrix (called Fibrogide) can be used to replace soft tissue taken from the subject. If the collagen matrix will prove to be equally as effective as the patient own tissue, it will be possible to avoid a more extensive surgery and decrease pain and discomfort.
Detailed description
Objectives Primary objective: to assess non-inferiority of differences in root coverage of recession defects comparing the use of Volume Stable Collagen Matrix (VCMX, Geistlich Fibro-Gide®) ed to the use of CTG at 12 months Secondary objectives: to assess if VCMX is non-inferior in terms of complete root coverage, percentage of root coverage and professional evaluation of aesthetics. Moreover, the study is also designed to test if VCMX Geistlich Fibro-Gide® reduces morbidity, shortens time to recovery and improves patient based related outcomes with respect to the use of autologous connective tissue graft harvested from the patient own palate when used to obtain root coverage of multiple adjacent gingival recessions. Moreover, as adverse events, complete root coverage, and professional evaluation of aesthetics will be assessed
Design and Outcomes This will be a parallel group, controlled, assessor-blind, randomized, multicenter, multinational, clinical trial.
The statistical design will be a non-inferiority trial in terms of the professional outcomes measuring root coverage and aesthetics and a superiority trial in terms of patients related outcomes.
Based on a recently completed and published RCT with similar design (Geistlich Mucograft® study), the sample size has been estimated in 80 subjects per treatment arm (about 200 recessions/arm) to be analyzed with a multilevel statistical approach and a non-inferiority margin of 0.25 mm in recession coverage. The non-inferiority margin has been set as 50% of the clinically relevant difference estimated at 0.5 mm.
Randomization will be performed by computer generated random codes, using random permuted blocks with a block size of 4 to avoid uneven splits and minimization for the key prognostic factor cigarette smoking. Allocation will be concealed to the surgeons until completion of preparation of the recipient bed by opaque envelopes. A central study registrar will perform patient registration.
Study locations will include academic centers and a practice-based research network in Italy, Germany, and Spain.
A single examiner, blind with respect to the treatment assignment, will perform all primary outcome measurements at each center. Trained personnel not involved with the surgical intervention will: i) administer patient questionnaires, ii) provide instructions and collect patient diaries. A single calibrated investigator with specific experience in using the specific score will centrally perform assessment of esthetic scores on standardized digital images.
A biostatistician blind with respect to treatment assignment will perform the analysis.
Interventions and Duration The two intervention groups will consist of surgery with connective tissue graft from the palate (standard of care control) and surgery with the application of Geistlich Fibro-Gide®. Experienced clinicians will deliver treatment consisting of root coverage surgery using coronally advanced flaps, the most utilized procedure for coverage of multiple recessions. Surgery will be standardized and the same procedures/materials will be employed to ensure consistency essentially as performed in the completed Mucograft study.
The total duration of the Followfollow-up of individual patients will be up to 1 year and extended to 3 years for the collection of long-term follow-up data.
Sample Size and Study Population Study population will consist of 160 subjects with a minimum of two adjacent RT1 and RT2 (with periodontal attachment <2 mm) recessions of the gingival margin (average 2.5 recessions per subject, of which one should be 3 mm or deeper) requiring surgical intervention for root coverage. Heavy smokers (>10 cigarette/day) will be excluded.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Coronally Advanced Flap plus Collagen Matrix | Experimental | Device: Volume stable collagen matrixCoronally Advanced Flap plus Collagen Matrix Tissue Substitute |
| Coronally Advanced Flap plus Autologous Connective Tissue Graft | Active comparator | Procedure: Autologous Connective Tissue Graft from the Hard PalateCurrent standard of care |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male and female, 18 to 70 years of age, with a minimum of two adjacent teeth with gingival recession (at least one with a depth ≥ 3 mm - RT1 or RT2 with 2 mm or less of interdental periodontal attachment loss) in anterior and premolar teeth in the maxilla and requiring surgical intervention, without medical contraindications to elective surgery. In case of recessions on five or more adjacent teeth, the teeth at the external sides will not be included in the study.
- At least 2 mm marginal keratinized tissue width and irrespective of soft tissue thickness prior therapy. The study should involve treatment naïve patients in terms of root coverage procedures. Prior therapy should include treatment of gingival inflammation, if present, instructions in non-traumatic oral hygiene, and reconstruction of the cemento-enamel junction with adhesive dental materials in case of cervical abrasion or erosion involving this structure
- Evidence of subject ability to achieve good oral hygiene and control gingivitis in the whole of the dentition (FMPS<25% and FMBS<25%)
- Ability to understand study procedures and to comply with them for the entire length of the study. Ability and willingness to give written informed consent.
Key exclusion criteria (17 listed)
- Presence of untreated periodontitis
- Persistence of uncorrected gingival trauma from tooth brushing
- Interdental attachment loss greater than 2 mm or furcation involvement in the experimental teeth
- Presence of less than 2 mm of keratinized tissue width
- Presence of severe tooth malposition, rotation or clinically significant super-eruption
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Volume stable collagen matrixAlso: FibrogideVolume stable collagen matrix obtained from porcine collagen after proprietary cross-linking by device manufacturer | Device | Coronally Advanced Flap plus Collagen Matrix |
| Autologous Connective Tissue Graft from the Hard PalateAlso: CTGAutologous connective tissue surgically harvested from the hard palate and transplanted in the area of gingival recession | Procedure or surgery | Coronally Advanced Flap plus Autologous Connective Tissue Graft |
Primary outcome
Root coverage
Time frame: 12 months
Difference in reduction in gingival recession (root coverage) between baseline and 12 months
3 secondary outcomes
Complete root coverage
Time frame: 12 months
Time to recovery
Time frame: The first two post-operative weeks
Oral Health Related Quality of Life
Time frame: 3, 6, 12, 24, and 36 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Gingival Recession, Plastic Surgery
Active, not recruiting
Advanced Platelet-Rich Fibrin and Coronally Advanced Flap for Gingival Recession Treatment
Gingival Recession
Recruiting
Comparison of Two Methods of Covering a Single Lower Front Tooth With Receded Gums
Recession, Gingival
RecruitingPhase 2/3
Evaluation of the Modified VISTA Technique Using ALB-PRF vs CTG in the Treatment of Multiple Miller Class III Recessions
Gingival Recession
Recruiting
Free Mucogingival Graft for Isolated Root Coverage
Free Mucogingival Grafts, Gingival Recession
Recruiting
Comparing CAF and TCAF With Soft Tissue Grafting for Treating Multiple Recessions in the Premandibula.
Gingival Recession, Localized, Gingival Recession, Plastic Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Maurizio Tonetti, DMD PhD principal investigator
The European Research Group on Periodontology (ERGOPerio)
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Volume stable collagen matrix and Autologous Connective Tissue Graft from the Hard Palate in people with Gingival Recession, Plastic Surgery, run by Maurizio Tonetti at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Italy, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maurizio Tonetti, DMD, PhD (393473289709, maurizio.tonetti@ergoperio.eu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Root coverage (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2025.